LY3841136 + Tirzepatide for Obesity

Phase 1

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline up to 42 weeks

Summary

This trial will test how safe and well-tolerated a new drug, LY3841136, is when given with another drug, tirzepatitide, to overweight and obese patients.

Who is the study for?

This clinical trial is for overweight and obese individuals who are interested in testing a new treatment. Specific eligibility criteria to join the study have not been provided, but typically participants must meet certain health conditions.

What is being tested?

The trial is evaluating the safety and tolerability of a drug called LY3841136 when used with another medication named tirzepatide. The study will track participant responses over a period of up to 42 weeks.

What are the potential side effects?

While specific side effects are not listed, common reactions to weight loss drugs can include gastrointestinal issues like nausea or diarrhea, headaches, increased heart rate, and potential allergic reactions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline up to 42 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline up to 42 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 42 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of Participants With One or More Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration